Xtant Medical Holdings Inc (XTNT)

Currency in USD
0.2381
+0.0220(+10.18%)
Real-time Data·
XTNT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.21700.2499
52 wk Range
0.17000.8400
Key Statistics
Prev. Close
0.2161
Open
0.234
Day's Range
0.217-0.2499
52 wk Range
0.17-0.84
Volume
164.09K
Average Vol. (3m)
1.66M
1-Year Change
-63.2562%
Book Value / Share
0.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XTNT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.7500
Upside
+214.99%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Xtant Medical Holdings Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.7500
(+214.99% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---DowngradeNov 16, 2026
Lucid Capital Markets
Buy1.00+319.99%-New CoverageSep 02, 2026
Craig-Hallum
Buy0.60+151.99%1.20MaintainAug 12, 2026
BTIG
Buy1.00+319.99%-MaintainMay 13, 2026
Maxim Group
Buy1.50+529.99%-New CoverageApr 20, 2026

Xtant Medical Holdings Inc Earnings Call Summary for Q3/2025

  • Xtant Medical reported Q3 2025 EPS of $0.01 (beating forecasted loss of $0.01), with revenue of $33.3 million (up 19% YoY), triggering a 7.75% premarket stock surge to $0.82.
  • The company reversed its previous year's $5 million net loss to achieve $1.3 million net income, with gross margin improving to 66.1% from 58.4% and adjusted EBITDA reaching $4.5 million.
  • CEO Sean Browne emphasized profitability as the company's primary focus, highlighting the launch of Trivium advanced demineralized bone matrix as a key product innovation.
  • Xtant provided 2025 revenue guidance of $131-$135 million (11-15% growth) and expects low double-digit growth in its orthobiologics segment for 2026.
  • A pending $19.2 million sale of non-core assets to Companion Spine is expected to reduce long-term debt, strengthening the company's financial position.
Last Updated: 11/11/2025, 09:15 AM
Read Full Transcript

Earnings

Latest Release
Nov 16, 2026
EPS / Forecast
-0.03 / -0.02
Revenue / Forecast
24.3M / 26.27M
EPS Revisions
Last 90 days

XTNT Income Statement

Compare XTNT to Peers and Sector

Metrics to compare
XTNT
Peers
Sector
Relationship
P/E Ratio
−1.9x−1.4x−0.2x
PEG Ratio
0.00−0.060.00
Price / Book
0.8x2.5x2.6x
Price / LTM Sales
0.3x2.8x2.7x
Upside (Analyst Target)
209.0%269.2%72.2%
Fair Value Upside
Unlock35.1%12.4%Unlock

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.87M2.05%591.38K
Other Institutional Investors
84.50M60.23%17.39M
Public Companies & Retail Investors
52.92M37.72%10.89M
Total
140.29M100.00%28.87M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Nantahala Capital Management, LLC48.75%68,394,00014,075
Lytton-Kambara Foundation5.01%7,026,1041,446

People Also Watch

153.93
LAMR
+1.26%
74.05
ASH
-0.10%
1.280
RBBN
-4.48%
3.951
ATYR
+7.06%
26.83
VIAV
-8.67%

FAQ

What Is the Xtant Medical (XTNT) Stock Price Today?

The Xtant Medical stock price today is 0.2381 USD.

What Stock Exchange Does Xtant Medical Trade On?

Xtant Medical is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Xtant Medical?

The stock symbol for Xtant Medical is "XTNT."

What Is the Xtant Medical Market Cap?

As of today, Xtant Medical market cap is 33.4000M USD.

What Is Xtant Medical's Earnings Per Share (TTM)?

The Xtant Medical EPS (TTM) is -0.11.

When Is the Next Xtant Medical Earnings Date?

Xtant Medical will release its next earnings report on Mar 09, 2027.

From a Technical Analysis Perspective, Is XTNT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Xtant Medical Stock Split?

Xtant Medical has split 2 times.

How Many Employees Does Xtant Medical Have?

Xtant Medical has 151 employees.

What is the current trading status of Xtant Medical (XTNT)?

As of Nov 20, 2026, Xtant Medical (XTNT) is trading at a price of 0.2381 USD, with a previous close of 0.2161 USD. The stock has fluctuated within a day range of 0.2170 USD to 0.2499 USD, while its 52-week range spans from 0.1700 USD to 0.8400 USD.

What Is Xtant Medical (XTNT) Price Target According to Analysts?

The average 12-month price target for Xtant Medical is 0.7500 USD, with a high estimate of 1 USD and a low estimate of 0.5 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +214.99% Upside potential.

What Is the XTNT Premarket Price?

XTNT's last pre-market stock price is 0.2200 USD. The pre-market share volume is 10.0000, and the stock has decreased by 0.0039, or 1.8000%.

What Is the XTNT After Hours Price?

XTNT's last after hours stock price is 0.2199 USD, the stock has decreased by 0.0038, or 1.7600%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.